1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis

Kreuter, Alexander; Sommer, Anna; Hyun, Julia; Bräutigam, Matthias; Brockmeyer, Norbert H.; Altmeyer, Peter; Gambichler, Thilo

doi:10.1001/archderm.142.9.1138

Cited by 60 publications

(68 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…77 In a 4-week, randomized, double-blind, placebo-controlled trial of 80 patients with intertriginous psoriasis, pimecrolimus was less efficacious than both calcipotriol and betamethasone. 78 was an investigator for Galderma and Genentech, re-…”

Section: Tacrolimus and Pimecrolimusmentioning

confidence: 99%

Guidelines of care for the management of psoriasis and psoriatic arthritis

Menter

Korman

Elmets

et al. 2009

Journal of the American Academy of Dermatology

427

190

View full text Add to dashboard Cite

Section: Tacrolimus and Pimecrolimusmentioning

confidence: 99%

Guidelines of care for the management of psoriasis and psoriatic arthritis

Menter

Korman

Elmets

et al. 2009

Journal of the American Academy of Dermatology

427

190

View full text Add to dashboard Cite

“…Instead, the BELIEVE study showed that monotherapy with adalimumab was more efficacious at week 16 than adalimumab combined with topical corticosteroids and vitamin D analogues [4]. The PASI75 responses between patients with and without prior anti-TNFs were similar for topical treatments regardless of whether the participants used calcipotriol +/– corticosteroids or placebo [3,5]. …”

Section: Introductionmentioning

confidence: 99%

Topical Treatment Habits in Psoriasis Patients Receiving Adalimumab

Kolios

Rusca²,

Reisenbauer³

et al. 2012

Dermatology

View full text Add to dashboard Cite

Background: Biologics are used increasingly to treat moderate-to-severe psoriasis. Here the topical treatment habits (corticosteroids and vitamin D derivates) and moisturizer use of 97 Swiss patients (male 65, female 32) receiving adalimumab have been evaluated. Methods: Using a short cross-sectional survey the pharmacist asked patients during telephone contact about their topical treatment habits and psoriasis activity. Results: 47 patients with adalimumab monotherapy were still free of psoriatic lesions after a longer follow-up of 13 months of therapy; 8 of them still used topical treatment. In contrast, 38 of 50 patients with remaining lesions used topicals. More than 75% of patients indicated that the perceived efficacy of additional topical therapy was ≥5 on a visual analog scale (0–10). The use of moisturizers did not correlate with disease activity. Conclusion: Topical treatment use by adalimumab patients is associated with remaining disease activity. 83% of patients without residual plaques (40% of all adalimumab patients) are able to stop topical treatment completely.

show abstract

“…Since 1980, calcitriol [9], calcipotriol [10], cyclosporin [11], tretinoin [12], and antibacterials have been used in the treatment of psoriasis, with a variety of major or minor adverse effects. Therefore, over the past few years, research has focused on efforts to find more effective and safe substances to treat psoriasis [13,14].…”

Section: Introductionmentioning

confidence: 99%

Effect of the Active Fraction of Flos Daturae on IFN-γ Induced Apoptosis in Immortalized Human Epidermal Keratinocyte Cells (HaCAT)

Tang¹,

Yang²,

Wang³

et al. 2011

TOPHARMCJ

View full text Add to dashboard Cite

Abstract:The present study is to investigate the effect of the active fraction of Flos Daturae (AF-FD) (dried flower of Datura metel L.) on IFN-induced apoptosis in a human keratinocyte cell line (HaCAT), which is a widely accepted mimic model of psoriasis. Accordingly, we used MTT and LDH to assay cell viability, FCM and Hoechst 33342 staining to assay cell apoptosis, and Western blotting to assay the expression of keratin 17 (K17). Administration of IFN-(5-125 U/mL) decreased MTT reduction and increased LDH leakage in a dose-dependent manner. Twenty-five U/mL IFN-elevated apoptosis significantly. The experimental results showed that AF-FD at the concentrations of 25 and 50 μg/mL alleviated the IFN--induced inhibition of MTT reduction by 12.58% and 17.51%, and decreased LDH leakage by 14.47% and 15.83%, respectively. Through FCM and Hoechst 33342 staining, it was found that AF-FD can lower IFN-induced apoptosis at the concentrations of 12.5-50 μg/mL. The administration of 25 μg/mL AF-FD attenuated the IFN-induced over-expression of K17 from 206.32% to 178.83%. The effect of AF-FD on K17 expression may play a key role in protecting HaCAT cells from apoptosis.

show abstract

1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis

Cited by 60 publications

References 8 publications

Guidelines of care for the management of psoriasis and psoriatic arthritis

Guidelines of care for the management of psoriasis and psoriatic arthritis

Topical Treatment Habits in Psoriasis Patients Receiving Adalimumab

Effect of the Active Fraction of Flos Daturae on IFN-γ Induced Apoptosis in Immortalized Human Epidermal Keratinocyte Cells (HaCAT)

Contact Info

Product

Resources

About